Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) FCF Margin (2016 - 2025)

Guided Therapeutics' FCF Margin history spans 15 years, with the latest figure at 461.67% for Q3 2025.

  • For Q3 2025, FCF Margin changed N/A year-over-year to 461.67%; the TTM value through Sep 2025 reached 623.03%, up 233223.0%, while the annual FY2024 figure was 15985.71%, 1420408.0% down from the prior year.
  • FCF Margin for Q3 2025 was 461.67% at Guided Therapeutics, down from 144.44% in the prior quarter.
  • Across five years, FCF Margin topped out at 258.33% in Q4 2021 and bottomed at 34800.0% in Q2 2021.
  • The 5-year median for FCF Margin is 2268.18% (2023), against an average of 8440.3%.
  • The largest annual shift saw FCF Margin surged 2748000bps in 2022 before it crashed -3215000bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 258.33% in 2021, then crashed by -7958bps to 20300.0% in 2022, then surged by 95bps to 1050.0% in 2023, then crashed by -3062bps to 33200.0% in 2024, then soared by 99bps to 461.67% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's FCF Margin are 461.67% (Q3 2025), 144.44% (Q2 2025), and 33200.0% (Q4 2024).